Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Several major U.S. health insurers announce they will voluntarily speed up and simplify the prior authorization process.

They have already taken the weight-loss sector by storm - now the blockbuster drugs Ozempic and Mounjaro could do the same ...

Novo Nordisk cut off Hims & Hers Health from selling lower-priced Wegovy on Monday morning, but its explanation for the ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug - Hims & Hers had partnered with ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Hims & Hers Health Inc.'s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the ...